Medicine Description finoxlab 10 mg
Finoxlab tablets represent a promising development in the treatment of chronic kidney disease (CKD), especially in adults who also suffer from type 2 diabetes. CKD is a serious and common complication of diabetes and can lead to progressive deterioration of kidney function and ultimately to end-stage renal failure, requiring dialysis or kidney transplantation. In addition, CKD significantly increases the risk of serious cardiovascular events. Finoxlab, the active ingredient in this drug, is a new generation mineralocorticoid receptor (MR) inhibitor and offers a unique mechanism of action that targets key pathways involved in kidney damage and the development of cardiovascular disease in this patient population.
The active ingredients in Finoxlab tablets
Each coated tablet of Finoxlab contains:
Finerenone: A selective nonsteroidal mineralocorticoid receptor antagonist (MRA). These receptors are located in the kidneys, heart, and blood vessels. Excessive activation of these receptors, often due to elevated aldosterone levels, leads to worsening inflammation, fibrosis (tissue scarring), and damage to blood vessels in the kidneys and heart. Finnerenone works by blocking aldosterone from binding to these receptors, thereby reducing these harmful effects. Finnerenone differs from conventional mineralocorticoid receptor antagonists in its chemical structure and receptor selectivity, which may contribute to an improved safety and efficacy profile.
Available Strengths
Venoxab tablets are currently available in one strength: 10 mg. The initial and subsequent doses are determined based on the patient's kidney function and serum potassium levels, and the doctor may adjust the dose accordingly.
Venoxab tablets are used to treat adults with chronic kidney disease (CKD) who also have type 2 diabetes. Treatment with venoxab aims to:
Reducing the risk of worsening kidney function: Helps slow the progression of CKD and maintain kidney function for longer.
Reducing the risk of end-stage kidney failure: Reduces the likelihood of needing dialysis or a kidney transplant.
Reducing the risk of cardiovascular death: Reduces the risk of death from cardiovascular problems.
Reducing the risk of hospitalization for heart failure: Reduces the likelihood of needing hospitalization for heart failure.